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Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neu-
tropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during
1986–1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly
absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia
for these groups were 20%, 26%, and 27%, respectively ( ). In a multivariate model without includingPp .0001
antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of
neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial
prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included,
the adjustment quality of the model improved slightly ( ), with an odds ratio of 1.19 (95% confidencePp .05
interval [CI], 0.92–1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07–1.88) for those who were
receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact
on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.
In a previous study that sought to identify, at the onset
of fever during neutropenia, those patients who will
eventually have documented bacteremia, we found ad-
ministration of antifungal prophylaxis to be an inde-
pendent prognostic factor for bacteremia. We found an
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OR estimate of 2.48, with 95% CI ranging from 1.49 to
4.13 on a derivation set of 558 episodes [1]. Although
lacking a satisfactory clinical explanation, our group [2]
and others [3–5] had already shown antifungal prophy-
laxis to be associated with a higher rate of bacteremia
among febrile and neutropenic patients, although it may
possibly be only a marker for other prognostic factors.
With the aim of exploring more deeply and in a larger
patient population the existence of a possible effect of
antifungal prophylaxis on the rate of documented bac-
teremia among febrile neutropenic patients, we reviewed
the whole experience of the International Antimicrobial
Therapy Cooperative Group (IATCG) of the European
Organization for Research and Treatment of Cancer
(EORTC).
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PATIENTS AND METHODS
Patients. We analyzed data for patients who were entered in
4 trials of empirical antibiotic therapy for patients with febrile
neutropenia that were undertaken by our cooperative group
from 1986 through 1994 [6–9]. Multiple patient entries were
not allowed in IATCG trials beginning in 1991 (trial IX) [8].
Therefore, to avoid a potential dependency between outcome
data, we analyzed only first patient entries in all trials, including
those in which multiple entries were allowed.
Statistical methods. The binary outcome we assessed was
the presence of documented bacteremia (“yes” or “no”). The
baseline characteristics of patients were analyzed by descriptive
statistics, by use of frequency tabulations for categorical or
categorized variables, and addition of summary parameters
(median and range) for continuous variables. Independent var-
iables were measured when the patient was randomized to a
treatment group, at the onset of fever, and were those retrievable
in the same way for all trials. Antifungal prophylaxis status was
classified into one of the following categories: no prophylaxis,
prophylaxis with only poorly absorbable agents, or prophylaxis
with at least 1 absorbable agent. Poorly absorbable agents in-
cluded amphotericin B, nystatin, cotrimoxazole, and micona-
zole. Absorbable agents included ketoconazole, fluconazole,
and itraconazole. Univariate analyses were done with x2 tests
for categorical variables and analyses of variance for continuous
variables.
To assess the impact of antifungal prophylaxis on the rate
of documented bacteremia, we first fitted the data with the best
logistic regression model without taking into account antifungal
prophylaxis. The modeled probability was the probability of
final documentation of bacteremia. The variables included in
the model were selected by means of a backward-forward step-
wise procedure on a restricted set of covariates selected ac-
cording to the results of univariate analysis. The coefficients of
the logistic equation were estimated with the maximum like-
lihood method, and the hypothesis of the equality to 0 of these
coefficients was tested by use of a likelihood ratio. All of the
reported probabilities were 2-tailed, and 95% CIs were com-
puted. In a second step, we reestimated the coefficients of the
model with the addition of antifungal prophylaxis, and we
compared the models by use of a likelihood ratio.
RESULTS
The characteristics of the 3080 patients with febrile neutropenia
who were grouped together are shown in table 1. These patients
were enrolled in the trials by 70 institutions during 1986–1994.
The table also includes the number of missing observations
according to each variable. The median age of patients was 38
years; 1309 patients (42%) were female, and 1619 (52%) had
acute leukemia. The median granulocyte count at trial entry
was 9 cells/L.0.04 10
Antifungal prophylaxis in EORTC-IATCG trials. Infor-
mation about the administration of antifungal prophylaxis was
available for 3002 of 3080 patients. Of those, 1322 (44%) did
not receive any antifungal prophylaxis, 835 (28%) received poorly
absorbable agents, and 845 (28%) received absorbable drugs. As
shown in table 2, the use of absorbable agents increased signif-
icantly over time (from 35 patients [5%] in the first trial to 514
[50%] in the last trial; x2 test for trend, 281.0; ). Char-P ! .0001
acteristics significantly associated with a higher rate of admin-
istration of antifungal prophylaxis were adult age ( ),P ! .001
smaller size of institution (expressed by the number of patients
entered in the trials), longer duration of hospitalization before
the development of fever, longer duration of granulocytopenia
(! 9 cells/L) before enrollment, a diagnosis of hematologic0.5 10
malignancy or bone marrow transplantation (BMT), having an
iv catheter in situ, and receiving antibacterial prophylaxis (P !
for each of the aforementioned characteristics)..0001
Factors associated with a diagnosis of bacteremia. A di-
agnosis of bacteremia was obtained in 708 (24%) of 3080 epi-
sodes of febrile neutropenia, and had a statistically significant
univariate relationship with the administration of antifungal
prophylaxis (x2 test for trend, 14.7; ). Indeed, the ratePp .0001
of bacteremia was 20% among patients not receiving any anti-
fungal prophylaxis, 26% among those receiving poorly absorb-
able agents, and 27% for those taking absorbable agents. Other
characteristics associated with a higher (univariate) risk of bac-
teremia were the following: diagnosis of hematologic malig-
nancy ( ), underlying disease in maintenance therapy orP ! .001
in relapse ( ), longer duration of granulocytopenia be-P ! .0001
fore fever ( ), granulocyte count ! 9 cells/LP ! .0001 0.1 10
( ), presence of an iv catheter ( ), temperatureP ! .0001 P ! .0001
at presentation 139C ( ), and status of septic shockP ! .0001
( ).P ! .0001
The covariates with values of in univariate analysisP ! .20
were then tested in a multivariate logistic regression model,
without including the antifungal prophylaxis status. The multi-
variate analysis included the following covariates: age, under-
lying disease and its status (onset or relapse), length of hospital
stay before enrollment, duration of granulocytopenia before
enrollment, presence of an iv catheter, presence of shock, tem-
perature, granulocyte count, and administration of antibacterial
prophylaxis. The specifications of the model are presented in
table 3 with OR estimates for the listed categories (an OR11
was associated with a higher rate of bacteremia). In this model,
the characteristics identified as independently associated with
a higher rate of documented bacteremia were age 130 years,
diagnosis of acute lymphoblastic leukemia, disease status dif-
ferent from acute leukemia in first induction treatment, longer
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Table 1. Characteristics of 3080 patients enrolled in study of
4 trials of antifungal prophylaxis and bacteremia.
Characteristic
(no. of patients with data missing)
No. of
patients
% of
total
sample
Trial [reference]
V [6] 688 22
VIII [7] 672 22
IX [8] 686 22
XI [9] 1034 34
Institution, no. of patients enrolled
!30 531 17
30–150 1596 52
1150 953 31
Sex
Male 1771 58
Female 1309 42
Age, y
!15 630 20
15–30 602 20
130 1848 60
Underlying disease (16)
Acute nonlymphocytic leukemia 1115 36
Acute lymphoblastic leukemia 504 16
Lymphoma 345 11
Solid tumor 377 12
BMT 548 18
Other condition 175 6
Disease status
First induction 876 28
Relapse 520 17
Maintenance 347 11
Not applicable 1337 43
Presence of an iv catheter at enroll-
ment (20)
None 741 24
Peripheral 349 11
Central 721 24
Hickman 934 31
TIC 278 9
Other 37 1
Antibacterial prophylaxis
No 1323 43
Yes 1757 57
Duration of hospitalization before enroll-
ment, d a(55)
0 711 24
1–10 850 28
110 1464 48
Duration of granulocytopenia before enrollment,
db (449)
0 203 8
1–5 1340 51
6–15 878 33
115 210 8
Granulocyte count at enrollment  109
cells/Lc (40)
!0.1 2068 68
0.1–0.499 665 22
0.5 307 10
(continued)
Characteristic
(no. of patients with data missing)
No. of
patients
% of
total
sample
Temperature at enrollment , Cd (25)
38.0–38.9 2041 67
39.0–39.9 901 29
40.0 113 4
Shock at enrollment (23)
No 3002 98
Yes 55 2
Site of infection at enrollment
No site detectable 1882 61
Upper respiratory tract 470 15
Lung 311 10
Gut 102 3
IV catheter 78 3
Other site 237 8
Antifungal prophylaxis (78)
None 1322 44
Poorly absorbable agent 835 28
Absorbable agent 845 28
NOTE. ALL, acute lymphoblastic leukemia; ANLL, acute nonlymphob-
lastic leukemia; BMT, bone marrow transplantation; TIC, totally implantable
catheter.
a Median, 10 d; range, 0–175 d.
b Range, 0–690 d.
c Median, 0.04; range, 0–0.998.
d Median, 38.6C; range, 38.0–41.5 C.
duration of in-hospital stay, granulocyte count ! 9 cells/0.1 10
L, presence of a central venous access other than a totally im-
plantable catheter, presence of fever 139C, and presence of
septic shock.
Impact of antifungal prophylaxis on the risk of bactere-
mia. Table 4 shows the coefficient estimates, with ORs and
CIs, of the model of factors including antifungal prophylaxis
that predict bacteremia. The addition of antifungal prophylaxis
slightly improved the quality of the model ( ), whereasPp .05
the ORs of the other variables remained similar to those iden-
tified in the logistic model, not including antifungal prophy-
laxis. This suggests that antifungal prophylaxis had a possible
prognostic value for documented bacteremia, which was in-
dependent from the variables previously considered. However,
only the CI for the category of absorbable agents did not overlap
1 (point estimate, 1.42; CI, 1.07–1.88), suggesting that the effect
on the rate of documented bacteremia was restricted to this
type of prophylaxis.
DISCUSSION
The possible role of antifungal prophylaxis with azole com-
pounds in increasing the rate of bacteremia among febrile neu-
tropenic patients was first raised by Palmblad et al. [4] in 1992.
In a small, randomized, double-blind trial of ketoconazole ver-
sus placebo, they found that the incidence of febrile episodes
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Table 2. Use of antifungal prophylaxis in trials of the
International Antimicrobial Therapy Cooperative Group of
the European Organization for Research and Treatment of
Cancer.
Antifungal
prophylaxis
Trial, year
V, 1991 VIII, 1993 IX, 1995 XI, 1996
No 329 (49) 355 (58) 298 (43) 340 (33)
Yes
PAA 304 (46) 195 (32) 156 (23) 180 (17)
AA 35 (5) 64 (10) 232 (34) 514 (50)
NOTE. Data are no. (%) of patients. x2 test for trend, P !
. PAA, poorly absorbable agent; AA, absorbable agent..0001
Table 3. Factors associated with documentation of bacteremia in 2507 case patients by logistic
regression model without including antifungal prophylaxis.
Covariate Coefficient SE OR (95% CI) P
Age 130 y (reference, 30 y) 0.32 0.11 1.38 (1.11–1.71) .003
Underlying disease (reference, acute nonlymphocytic
leukemia)
!.0001
Acute lymphoblastic leukemia 0.40 0.14 1.49 (1.13–.96) .005
Other 0.45 0.12 0.64 (0.50–0.81) !.001
Disease status other than first induction (reference,
first induction)
0.60 0.12 1.82 (1.44–2.31) !.0001
Hospitalization, d (reference, 0) !.0001
1–10 0.36 0.17 1.43 (1.03–2.00) .04
110 0.80 0.16 2.23 (1.63–3.05) !.0001
Granulocytopenia, d (reference, 0) .001
1–15 0.50 0.24 1.64 (1.03–2.64) .04
115 0.98 0.28 2.65 (1.54–4.61) !.001
IV catheter (reference, none) .009
Central/Hickman 0.39 0.15 1.48 (1.10–1.98) .008
Peripheral 0.24 0.20 1.27 (0.86–1.88) .23
TIC 0.03 0.21 1.03 (0.68–1.56) .90
Shock (reference, none) 1.66 0.32 5.24 (2.81–9.85) !.0001
Antibacterial prophylaxis (reference, none) 0.25 0.11 0.78 (0.63–0.97) .02
Temperature, C (reference, 38.0–38.9C) !.0001
39.0–39.9 0.60 0.10 1.82 (1.50–2.22) !.0001
40.0 1.50 0.23 4.51 (2.86–7.03) !.0001
Granulocyte count 0.1  109 cells/L (reference, !0.1) 0.37 0.12 0.69 (0.55–0.87) .002
NOTE. OR11 was associated with a higher rate of bacteremia. TIC, totally implantable catheter.
was the same in both groups but that the administration of
ketoconazole was apparently affecting the type of fever docu-
mentation. Indeed, the rate of bacteremia was higher among
patients who received ketoconazole than among those who re-
ceived placebo (74% vs. 37%). Because of the small size of the
study (107 patients), there was the possibility that this difference
was due to chance. However, similar results were also reported
by Schaffner and Schaffner [5] in a slightly larger study of
fluconazole versus placebo. They reported a 36% incidence rate
of bacteremia in fluconazole recipients versus 21% in placebo
recipients. Both studies found some evidence suggesting that
this effect might have been related to a longer duration of
neutropenia in patients receiving antifungal prophylaxis.
In a randomized, prospective study of fluconazole prophy-
laxis, Kern et al. [10] also found that microbiologically docu-
mented infections were more frequent among patients who
received fluconazole (50% vs. 31%) and that this was mainly
due to a higher incidence rate of bacteremia (42% vs. 22%).
More recently, in a large prospective, randomized clinical trial
of itraconazole oral solution versus placebo, Menichetti et al.
[11] again found a higher rate of bacteremia among patients
who were receiving prophylaxis. Although the duration of neu-
tropenia was the same in both groups, the rate of bacteremia
was 23% among itraconazole recipients versus 15% among
placebo recipients ( ). As reviewed by Palmblad [12],Pp .037
other authors apparently did not find the same effect, although
the incidence of bacteremia was rarely reported in these studies.
The present study shows that antifungal prophylaxis, espe-
cially with absorbable antibiotics, has been administered with
increasing frequency over 10 years, at least among patients
entered in the 4 trials performed by the IATCG of the EORTC.
This was likely related to the impact of 2 large clinical trials
that showed that fluconazole, at dosages of 400 mg/day, was
able to reduce the incidence of fungal infections in patients
undergoing allogeneic BMT [13, 14]. However, our data show
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Table 4. Factors associated with documentation of bacteremia in 2507 case patients by logistic
regression model including antifungal prophylaxis.
Covariate Coefficient SE OR (95% CI) P
Age 130 y (reference, 30 y) 0.31 0.11 1.37 (1.10–1.69) .004
Underlying disease (reference, acute nonlymphocytic
leukemia)
!.0001
Acute lymphoblastic leukemia 0.41 0.15 1.51 (1.12–2.02) .005
Other 0.45 0.12 0.64 (0.50–0.81) !.001
Disease status other than first induction (reference,
first induction)
0.59 0.13 1.81 (1.40–2.33) !.0001
Hospitalization, d (reference, 0) !.0001
1–10 0.31 0.18 1.36 (0.96–1.94) .08
110 0.73 0.17 2.07 (1.49–2.90) !.0001
Granulocytopenia, d (reference, 0) .002
1–15 0.49 0.24 1.64 (1.02–2.61) .04
115 0.97 0.28 2.63 (1.52–4.57) !.001
IV catheter (reference, none) .05
Central/Hickman 0.33 0.15 1.39 (1.04–1.87) .03
Peripheral 0.29 0.20 1.34 (0.90–1.98) .14
TIC 0.05 0.22 0.96 (0.62–1.46) .83
Shock (reference, none) 1.70 0.33 5.47 (2.86–10.5) !.0001
Antibacterial prophylaxis (reference, none) 0.36 0.12 0.70 (0.55–0.88) .003
Temperature, C (reference, 38.0–38.9C) !.0001
39.0–39.9 0.64 0.11 1.90 (1.54–2.35) !.0001
40.0 1.60 0.23 4.95 (3.14–7.81) !.0001
Granulocyte count 0.1  109 cells/L (reference, !0.1) 0.38 0.12 0.69 (0.54–0.87) .002
Antifungal prophylaxis (reference, none) .05
Poorly absorbable agent 0.18 0.13 1.19 (0.92–1.55) .19
Absorbable agent 0.35 0.14 1.41 (1.07–1.88) .01
NOTE. TIC, totally implantable catheter.
that antifungal prophylaxis might have an impact on the rate
of documented bacteremia. Indeed, in univariate analysis we
found a statistically significant increasing rate of bacteremia
correlated with the administration of antifungal prophylaxis.
When analyzing this phenomenon in a multivariate setting,
we found that administration of antifungal prophylaxis im-
proved the quality of the model predicting bacteremia, showing
a possible true impact of this procedure on the rate of bacte-
remia. As suggested by the OR and CI, this effect seems to be
relevant mainly for patients receiving absorbable drugs. More-
over, our data indicate that there is no confounding relationship
between antifungal prophylaxis and other variables significantly
associated with the rate of documented bacteremia, thus con-
firming the possible independent role of antifungal prophylaxis,
especially with absorbable drugs. We recognize that this variable
might be a marker for other variables not recorded in our
database. In addition we also recognize that changes might have
occurred during the time of study, potentially able to affect the
results of the analysis (e.g., type and frequency of antifungal
prophylaxis, intensity of chemotherapy, and use of growth fac-
tors). For this reason, we believe that only studies prospectively
designed with the purpose of evaluating this possible effect as
a prespecified hypothesis might be able to give a definitive
answer to this question.
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